I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Sleep-related problems are common nonmotor symptoms in Parkinson\'s disease (PD); the sleep-related problems most prevalent in PD are insomnia, rapid eye movement (REM) sleep behavior disorder (RBD), obstructive sleep apnea (OSA), excessive daytime sleepiness, and periodic leg movement syndrome. The prevalence of these disorders ranges between 60% and 98%.\[[@ref1][@ref2][@ref3]\] Approximately 30.0--62.5% of PD patients have RBD,\[[@ref2][@ref4][@ref5]\] which is characterized by atonia occurring typically in REM sleep. These patients tend to have the akinetic-rigid dominant subtype of PD and exhibit severe cognitive impairment and other nonmotor symptoms.\[[@ref5]\]

Epidemiological studies suggested that OSA is another common sleep-related disorder in PD.\[[@ref6][@ref7]\] Previous studies reported the frequency of OSA in PD patients between 20% and 66%.\[[@ref8]\] Upper airway obstruction plays a critical role in the pathogenesis of OSA.\[[@ref9]\] Reduced upper airway dilator muscle activity at sleep results in an obstructive respiratory event. Notably, excessive muscle activity as evaluated by electromyography (EMG) in RBD\[[@ref10]\] may contribute to preventing upper airway closure.\[[@ref11]\] This phenomenon has been verified in idiopathic RBD patients but remains controversial in PD. Although we found that patients with PD and RBD experienced less OSA symptoms, another study presented the opposite conclusion.\[[@ref12]\]

The prevalence of cognitive impairment in PD patients is approximately 30% but increases to 75--90% at 10-year follow-up.\[[@ref13][@ref14]\] PD patients with RBD exhibit worse cognition, especially executive/attention and memory functions.\[[@ref15][@ref16][@ref17]\] Emerging evidence indicates that, in the healthy population, cognitive impairment is a severe OSA complication.\[[@ref18]\] In PD, OSA may be associated with increased nonmotor symptoms, particularly cognitive dysfunction.\[[@ref19]\] However, considering RBD may relieve hypoxemia in PD patients with OSA, whether this amelioration protects against cognitive decline is unclear.

As the relationship between OSA and RBD in PD patients remains unclear, we performed extensive clinical evaluations and overnight polysomnography (PSG) to explore whether RBD could alleviate OSA severity in PD patients and investigate the effect of hypoxemia and RBD on cognitive impairment in PD patients.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

This study was approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University, and all patients provided written informed consent.

Participants {#sec2-2}
------------

From February 2014 to May 2017, we recruited 224 PD patients from the Department of Neurology at the Second Affiliated Hospital of Soochow University. Study participants were diagnosed with PD using the United Kingdom PD Society Brain Bank clinical diagnosis criteria.\[[@ref20]\] All the participants had at least 5 years of schooling. We excluded 38 of the recruited PD patients because of problems arising during PSG or the presence of major depression or anxiety as defined by the Diagnostic Statistical Manual-IV criteria. Considering the potential cognitive impairment in patients with hypertension and diabetes, patients with blood pressure either systolic blood pressure \>160 mmHg (1 mmHg = 0.133 kPa) or diastolic blood pressure \>100 mmHg or diabetes were excluded as well. After excluding the above patients, 174 patients remained.

Clinical assessment {#sec2-3}
-------------------

We collected demographic information, past medical history, and medications on all participants. We evaluated motor manifestations of PD patients in the "off" state and cognitive assessment in the "on" state. The clinical manifestations included the Unified Parkinson\'s Disease Rating Scale, Hoehn and Yahr stage. The Levodopa-equivalent daily dose was calculated according to the method described by Tomlinson *et al*.\[[@ref21]\] We assessed cognition by the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). We evaluated daytime somnolence and quality of life using the Epworth Sleepiness Scale (ESS) and the PD Questionnaire, respectively.

For analysis, we divided the PD patients into categories based on whether they had RBD or OSA. [Table 1](#T1){ref-type="table"} contains data on the comparison of demographic characteristics and PSG results of PD patients with and without RBD. [Table 2](#T2){ref-type="table"} contains data on the comparison of demographic characteristics and PSG results of PD patients with and without OSA. Patients were further classified into four groups in [Table 3](#T3){ref-type="table"}: PD group (PD without OSA or RBD), PD + OSA group (PD patients with OSA only), PD + RBD group (PD patients with RBD only), and PD + RBD + OSA group (PD with both RBD and OSA).

###### 

Clinical and polysomnography characteristics in PD patients with and without RBD

  Characteristics           PD without RBD (*n* = 82)   PD with RBD (*n* = 92)   Statistics   *P*
  ------------------------- --------------------------- ------------------------ ------------ ---------
  Sex (male/female), *n*    45/37                       68/24                    6.319\*      0.012
  Age (years)               64.0 ± 9.3                  65.1 ± 5.8               −0.915^†^    0.362
  BMI (kg/m^2^)             24.1 ± 3.3                  23.9 ± 2.7               0.514^†^     0.608
  Duration (years)          3.0 (1.0--5.0)              3.0 (1.0--5.0)           −1.378^‡^    0.168
  Education (years)         8.8 ± 3.2                   8.4 ± 3.5                0.966^†^     0.336
  UPDRS III                 23.70 ± 11.54               24.33 ± 9.98             −0.387^†^    0.700
  H-Y                       2.0 (1.5--2.5)              2.0 (1.5--2.5)           −0.810^‡^    0.418
  LED (mg/d)                300.0 (75.0--450.0)         300.0 (100.0--450.0)     −0.534^‡^    0.593
  MMSE                      27.01 ± 2.12                25.55 ± 2.13             4.532^†^     \<0.001
  MoCA                      24.61 ± 2.36                22.30 ± 2.43             6.363^†^     \<0.001
  Depression score          7.50 (4.00--13.00)          8.00 (4.00--15.00)       −0.314^‡^    0.753
  Anxiety score             6.00 (2.00--10.00)          7.00 (2.00--9.00)        −0.364^‡^    0.715
  ESS                       5.00 (3.00--7.00)           7.00 (4.00--10.00)       −2.681^‡^    0.007
  PDQ                       15.50 (9.00--26.00)         17.00 (9.00--34.00)      −1.161^‡^    0.246
  TST (min)                 341.28 ± 107.91             328.65 ± 104.60          0.988^†^     0.324
  SE (%)                    63.01 ± 18.52               60.22 ± 17.81            1.268^†^     0.206
  SL (min)                  14.00 (2.50--29.00)         13.50 (2.50--38.00)      −0.248^‡^    0.804
  Awakenings (times)        22.0 (17.0--31.0)           22.0 (16.0--29.0)        −0.089^‡^    0.929
  NREMS1 (%)                13.50 (8.80--18.60)         17.20 (10.00--26.20)     −1.880^‡^    0.060
  NREMS2 (%)                50.57 ± 17.50               46.35 ± 16.15            2.184^†^     0.089
  SWS (%)                   16.10 (8.60--24.30)         16.40 (8.60--26.30)      −0.372^‡^    0.710
  REMS (%)                  14.30 (6.30--22.10)         14.60 (9.70--20.50)      −0.916^‡^    0.360
  AHI (/h)                  0.80 (0.00--6.10)           1.40 (0.00--5.70)        −0.612^‡^    0.541
  ODI (/h)                  1.15 (0.00--5.55)           1.80 (0.20--6.30)        −0.505^‡^    0.613
  Min SaO~2~ (%)            88.94 ± 6.95                90.47 ± 3.35             −1.283^†^    0.201
  Min SaO~2~ in REM (%)     90.38 ± 6.78                92.11 ± 2.76             −0.307^†^    0.023
  Min SaO~2~ in NREM (%)    90.72 ± 4.73                90.74 ± 3.59             0.667^†^     0.506
  Tonic EMG activity (%)    1.98 (0.61--11.19)          21.95 (16.52--35.90)     −4.924^‡^    \<0.001
  Phasic EMG activity (%)   3.05 (0.50--8.33)           19.42 (15.00--30.42)     −5.344^‡^    \<0.001

Values are *n*, mean ± SD, or median (IQR). These analyses were performed using \*Chi-square test, ^†^independent Student's *t*-test, and ^‡^nonparametric tests. PD: Parkinson's disease; RBD: Rapid eye movement sleep behavior disorder; LED: Levodopa-equivalent daily dose; BMI: Body mass index; UPDRS: Unified Parkinson's Disease Rating Scale; H-Y: Hoehn and Yahr stage; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; ESS: Epworth Sleepiness Scale; PDQ: Parkinson's Disease Questionnaire; TST: Total sleep time; SE: Sleep efficiency; SL: Sleep latency; REMS: Rapid eye movement sleep; NREMS: Non-REMS; SWS: Slow wave sleep; AHI: Apnea-hypopnea index; ODI: Oxygen desaturation index; SaO~2~: Oxygen saturation; EMG: Electromyography; REM: Rapid eye movement; NREM: Non-REM; SD: Standard deviation; IQR: Interquartile range.

###### 

Clinical and polysomnography characteristics in PD patients with and without OSA

  Characteristics           PD without OSA (*n* = 114)   PD with OSA (*n* = 60)   Statistics   *P*
  ------------------------- ---------------------------- ------------------------ ------------ ---------
  Sex (male/female), *n*    72/42                        41/19                    0.462\*      0.496
  Age (years)               63.8 ± 7.7                   66.0 ± 7.5               −1.844^†^    0.067
  BMI (kg/m^2^)             23.6 ± 2.9                   24.8 ± 3.1               −2.541^†^    0.012
  Duration (years)          3.0 (1.0--6.0)               3.0 (2.0--4.0)           −0.367^‡^    0.714
  Education (years)         8.7 ± 3.5                    8.4 ± 3.0                0.673^†^     0.502
  UPDRS III                 23.54 ± 11.12                24.97 ± 9.96             −0.836^†^    0.780
  H-Y                       2.0 (1.5--2.5)               2.0 (1.5--2.5)           −0.279^‡^    0.671
  LED (mg/d)                300.0 (37.5--450.0)          300.0 (112.5--437.5)     −0.395^‡^    0.693
  MMSE                      26.57 ± 2.24                 25.63 ± 2.14             2.664^†^     0.008
  MoCA                      23.66 ± 2.69                 22.92 ± 2.56             1.758^†^     0.081
  HRSD                      9.00 (3.00--15.00)           7.00 (4.00--9.50)        −1.254^‡^    0.210
  HAMA                      6.00 (2.00--10.00)           5.00 (1.50--8.00)        −0.966^‡^    0.334
  ESS                       6.00 (3.00--9.00)            5.50 (3.00--8.50)        −0.550^‡^    0.582
  PDQ                       16.00 (8.00--33.00)          17.00 (13.00--23.25)     −0.921^‡^    0.357
  TST (min)                 329.7 ± 106.0                338.3 ± 104.0            −0.514^†^    0.608
  SE (%)                    60.90 (47.20--74.60)         67.90 (48.70--76.35)     −0.997^‡^    0.319
  SL (min)                  13.25 (1.38--28.63)          15.75 (5.25--35.88)      −1.286^‡^    0.199
  Awakenings (times)        21.0 (16.0--31.3)            22.5 (16.3--28.8)        −0.116^‡^    0.908
  NREMS1 (%)                13.25 (6.80--23.05)          16.50 (11.78--24.53)     −2.045^‡^    0.041
  NREMS2 (%)                47.87 ± 17.98                48.33 ± 14.16            −0.174^†^    0.862
  SWS (%)                   16.15 (9.50--26.50)          17.45 (6.60--24.18)      −0.253^‡^    0.800
  REMS (%)                  14.50 (8.28--22.83)          14.20 (7.55--20.10)      −0.667^‡^    0.505
  AHI (/h)                  0.00 (0.00--1.23)            10.20 (5.73--22.08)      −10.772^‡^   \<0.001
  ODI (/h)                  0.35 (0.00--1.50)            9.00 (4.70--19.70)       −9.220^‡^    \<0.001
  Min SaO~2~ (%)            91.83 ± 2.33                 85.98 ± 6.76             6.507^†^     \<0.001
  Min SaO~2~ in REM (%)     93.17 ± 2.61                 88.48 ± 5.71             6.289^†^     \<0.001
  Min SaO~2~ in NREM (%)    92.65 ± 1.82                 87.38 ± 4.25             9.169^†^     \<0.001
  Tonic EMG activity (%)    16.09 (6.75--21.34)          19.72 (1.83--443.67)     −1.268^‡^    0.205
  Phasic EMG activity (%)   11.45 (6.13--17.60)          16.36 (3.15--39.50)      −0.800^‡^    0.423

Values are *n*, mean ± SD, or median (IQR). These analyses were performed using \*Chi-square test, ^†^independent Student's *t*-test, and ^‡^nonparametric tests. PD: Parkinson's disease; RBD: Rapid eye movement sleep behavior disorder; LED: Levodopa-equivalent daily dose; BMI: Body mass index; UPDRS: Unified Parkinson's Disease Rating Scale; H-Y: Hoehn and Yahr stage; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; ESS: Epworth Sleepiness Scale; PDQ: Parkinson's Disease Questionnaire; TST: Total sleep time; SE: Sleep efficiency; SL: Sleep latency; REMS: Rapid eye movement sleep; NREMS: Non-REMS; SWS: Slow wave sleep; AHI: Apnea-hypopnea index; ODI: Oxygen desaturation index; SaO~2~: Oxygen saturation; EMG: Electromyography; OSA: Obstructive sleep apnea; SD: Standard deviation; IQR: Interquartile range; HRSD: Hamilton Rating Scale for Depression; HAMA: Hamilton Anxiety Rating Scale.

###### 

Clinical and polysomnography characteristics in PD patients with and without OSA and RBD

  Characteristics          PD (*n* = 53)       PD + OSA (*n* = 29)        PD + RBD (*n* = 61)   PD + RBD + OSA (*n* = 31)   Statistics   *P*
  ------------------------ ------------------- -------------------------- --------------------- --------------------------- ------------ ---------
  Sex (male/female), *n*   28/25               17/12                      44/17                 24/7                        7.429\*      0.059
  Age (years)              62.8 ± 9.3          65.7 ± 8.8                 64.7 ± 5.9            66.4 ± 6.2                  1.773^†^     0.154
  BMI (kg/m^2^)            23.5 ± 3.0          25.3 ± 3.6                 23.6 ± 2.8            24.3 ± 2.4                  2.748^†^     0.045
  Duration (years)         2.0 (1.0--5.5)      3.0 (1.1--4.5)             3.0 (1.5--5.0)        3.0 (2.0--4.0)              2.316^†^     0.509
  Education (years)        9.2 ± 3.4           8.4 ± 3.0                  8.3 ± 3.6             8.3 ± 3.2                   0.724^†^     0.539
  UPDRS III                24.71 ± 1.42        23.75 ± 1.86               22.36 ± 1.29          26.53 ± 1.81                1.262^‡^     0.289
  H-Y                      2.0 (1.5--2.5)      2.0 (1.5--2.5)             2.0 (1.5--2.5)        2.0 (1.5--2.5)              1.205^¦^     0.752
  LED (mg/d)               310.67 ± 22.67      320.05 ± 30.14             285.97 ± 20.60        303.93 ± 29.92              0.358^‡^     0.783
  MMSE                     27.42 ± 0.26        26.39 ± 0.35^\|\|^         25.73 ± 0.24^¶^       25.20 ± 0.35\*\*            10.480^‡^    \<0.001
  MoCA                     24.99 ± 0.31        24.08 ± 0.41               22.37 ± 0.28^¶^       22.27 ± 0.40\*\*            15.951^‡^    \<0.001
  HRSD                     9.43 ± 0.97         7.48 ± 1.28                9.94 ± 0.87           8.17 ± 1.27                 1.065^‡^     0.366
  HAMA                     6.55 ± 0.77         5.40 ± 1.02                7.28 ± 0.70           5.75 ± 1.02                 0.988^‡^     0.400
  ESS                      6.24 ± 0.62         5.74 ± 0.84                6.91 ± 0.56           7.14 ± 0.81                 0.668^‡^     0.573
  PDQ-39                   19.64 ± 1.85        20.77 ± 2.43               20.51 ± 1.66          22.97 ± 2.41                0.396^‡^     0.756
  TST (min)                329.00 ± 15.20      350.50 ± 20.16             326.40 ± 13.80        336.40 ± 13.80              0.359^‡^     0.783
  SE (%)                   61.03 ± 2.58        64.35 ± 3.43               58.74 ± 2.35          63.26 ± 3.41                0.766^‡^     0.515
  SL (min)                 21.14 ± 6.89        36.12 ± 9.14               37.13 ± 6.26          20.45 ± 9.10                1.536^‡^     0.207
  Awakenings (times)       24.0 ± 1.7          21.3 ± 2.2                 23.6 ± 1.5            25.5 ± 2.2                  0.624^‡^     0.601
  NREMS1 (%)               18.96 ± 1.81        17.19 ± 2.40               17.73 ± 1.64          22.77 ± 2.38                1.238^‡^     0.298
  NREMS2 (%)               50.85 ± 2.34        48.30 ± 3.11               44.80 ± 2.13          48.34 ± 3.09                1.209^‡^     0.308
  SWS (%)                  15.35 ± 1.76        19.15 ± 2.34               20.71 ± 1.60          17.26 ± 2.32                1.781^‡^     0.153
  REMS (%)                 14.16 ± 4.86        14.16 ± 6.46               23.84 ± 4.41          14.33 ± 6.41                0.995^‡^     0.397
  AHI (/h)                 0.20 (0.00--0.80)   7.90 (5.90--21.15)^\|\|^   0.00 (0.00--1.45)     10.90 (5.70--23.00)^††^     111.070^¦^   \<0.001
  ODI (/h)                 0.20 (0.00--1.20)   9.00 (4.03--16.75)^\|\|^   0.40 (0.00--1.80)     9.00 (6.00--21.40)^††^      85.987^¦^    \<0.001
  Min SaO~2~ (%)           92.36 ± 0.62        84.25 ± 0.82^\|\|^         91.34 ± 0.56          87.48 ± 0.81\*\*^,††^       25.570^‡^    \<0.001
  Min SaO~2~ in REM (%)    93.33 ± 0.57        86.74 ± 0.76^\|\|^         93.54 ± 0.52          90.00 ± 0.75\*\*^,††^       22.856^‡^    \<0.001
  Min SaO~2~ in NREM (%)   93.15 ± 0.42        87.63 ± 0.56^\|\|^         92.24 ± 0.38          87.15 ± 0.55^††^            39.965^‡^    \<0.001

Values are mean ± SD or median (IQR). The *P* value reflects differences among the four groups. These analyses were performed using \*Chi-square test, ^†^one-way analysis of variance, ^‡^analysis of covariance (adjusted for age, sex, duration, insomnia, and restless leg symptom. MMSE and MoCA were adjusted for education additionally), and ^§^nonparametric tests. ^\|\|^Significance between PD and PD + OSA groups; ^¶^Significance between PD and PD + RBD groups; \*\*Significance between PD + OSA and PD + RBD + OSA groups; ^††^Significance between PD + RBD and PD + RBD + OSA groups. PD: Parkinson's disease; RBD: Rapid eye movement sleep behavior disorder; LED: Levodopa-equivalent daily dose; BMI: Body mass index; UPDRS: Unified Parkinson's Disease Rating Scale; H-Y: Hoehn and Yahr stage; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; ESS: Epworth Sleepiness Scale; PDQ: Parkinson's Disease Questionnaire; TST: Total sleep time; SE: Sleep efficiency; SL: Sleep latency; REMS: Rapid eye movement sleep; NREMS: Non-REMS; SWS: Slow wave sleep; AHI: Apnea-hypopnea index; ODI: Oxygen desaturation index; SaO~2~: Oxygen saturation; SD: Standard deviation; OSA: Obstructive sleep apnea; IQR: Interquartile range.

Polysomnography {#sec2-4}
---------------

All patients underwent an overnight video-PSG study. Experienced PSG technologists and clinicians scored sleep stages, awakenings, and respiratory-related parameters, including apnea-hypopnea index (AHI), oxygen desaturation index (ODI), and minimum oxygen saturation (SaO~2~) in REM and non-REM (NREM) sleep according to the American Academy of Sleep Medicine (AASM) guidelines.\[[@ref22][@ref23]\] RBD was diagnosed according to the International Classification of Sleep Disorders Third Edition criteria using the PSG and clinical evaluations. The tonic chin EMG activity (tonic density) and the phasic chin EMG density activity (phasic density) were calculated according to a previously published method\[[@ref24]\] and AASM criteria. OSA was diagnosed if PSG evaluation yielded an AHI ≥5/h.

Statistical analysis {#sec2-5}
--------------------

We used SPSS software version 19.0 (SPSS Inc., Chicago, IL, USA) for the statistical analysis. Data were represented as the mean ± standard deviation (SD) or median (interquartile range). Comparisons were performed using independent Student\'s *t*-test or Chi-square test for clinical and PSG variables. Analysis of covariance or logistic regression models were used for adjusted comparisons of continuous and categorical data, respectively. The data were adjusted for age, sex, disease duration, insomnia, and restless leg symptoms. MMSE and MoCA results also were adjusted for education.\[[@ref25]\] Linear regression analysis was used to assess for trends in MoCA and index of OSA or RBD. A *P* \< 0.05 was considered statistically significant. A *P* \< 0.013 was considered to meet the threshold for significance in the Bonferroni *post hoc* test.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Of the 174 PD patients, 113 were men and 61 were women. The mean age of participants was 64.6 ± 7.7 years, and the mean education duration was 8.6 ± 3.4 years. Ninety-two patients (52.3%) had RBD and 60 (34.5%) had OSA.

Clinical and polysomnography characteristics in Parkinson\'s disease with and without rapid eye movement sleep behavior disorder or obstructive sleep apnea {#sec2-6}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

[Table 1](#T1){ref-type="table"} illustrates the clinical characteristics and PSG results from PD patients with and without RBD. We found no significant difference in PD motor symptoms and sleep structure between the two groups. PD patients with RBD performed significantly worse in MMSE (27.01 ± 2.12 vs. 25.55 ± 2.13, *t* = 4.532, *P* \< 0.001) and MoCA (24.61 ± 2.36 vs. 22.30 ± 2.43, *t* = 6.363, *P* \< 0.001) than patients without RBD. The median ESS score in PD patients with RBD was higher (7.00 \[4.00--10.00\] vs. 5.00 \[3.00--7.00\], *U* = −2.681, *P* = 0.007) than that in PD patients without RBD. PD patients with RBD had significantly higher percentages of tonic and phasic EMG activity than patients without RBD. We found no significant difference in AHI, ODI, and SaO~2~ during the whole sleep period between the two groups. We further explored the difference in minimum SaO~2~ between REM and NREM sleep. We found that PD patients with RBD had higher minimum SaO~2~ during REM sleep that those without RBD (90.38 ± 6.78% vs. 92.11 ± 2.76%, *t* = −0.307, *P* = 0.023).

[Table 2](#T2){ref-type="table"} summarizes the results of our comparison between PD patients with and without OSA. PD patients with OSA had higher AHI and ODI and lower minimum SaO~2~ compared with those without OSA. Their proportion of time in NREM sleep stage 1 was higher, and they performed worse in MMSE (25.63 ± 2.14 vs. 26.57 ± 2.24, *t* = 2.664, *P* = 0.008).

Clinical and polysomnographic characteristics in Parkinson\'s disease patients with and without obstructive sleep apnea and rapid eye movement sleep behavior disorder {#sec2-7}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

The clinical and PSG characteristics of PD, PD + OSA, PD + RBD, and PD + RBD + OSA patients are presented in [Table 3](#T3){ref-type="table"}. Comparisons of the clinical symptoms and PSG parameters among the groups were adjusted for age, sex, duration of disease, insomnia, and restless leg symptoms. Comparisons of the MMSE and MoCA scores were also adjusted for education. PD + RBD patients had worse MMSE and MoCA scores than those without. PD + OSA patients performed worse in MMSE than that in PD group as well. Aside from these differences, we found no statistically significant differences in clinical features among the four groups. Obviously, AHI, ODI, and minimum SaO~2~ in NREM sleep were higher in the PD + OSA and PD + RBD + OSA groups as compared with those in the PD and PD + RBD groups, respectively. Both during whole sleep and in REM sleep, PD + RBD + OSA patients had higher minimum SaO~2~ than that of PD + OSA patients.

Montreal Cognitive Assessment scores in Parkinson\'s disease patients with and without obstructive sleep apnea and rapid eye movement sleep behavior disorder {#sec2-8}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

[Figure 1](#F1){ref-type="fig"} displays the MoCA domain scores and the comparisons of the scores among the four groups. The results were adjusted for age, sex, duration of disease, and education. The PD + RBD and PD + RBD + OSA groups performed worse in visuospatial/executive function, attention, and delayed recall compared with the PD group. However, the PD + RBD + OSA group did not perform significantly worse than the PD + RBD group. Only in the delayed recall domain did the PD + OSA group have worse scores than the PD group have.

![Different domains of MoCA in PD patients with and without OSA or RBD. These analyses were performed using analysis of covariance (adjusted for age, sex, duration of disease, and education) and Bonferroni *post hoc* test (\**P* \< 0.013). PD: PD without OSA or RBD group, *n* = 53; PD + OSA: PD patients with OSA only, *n* = 29; PD + RBD: PD patients with RBD only, *n* = 61; PD + RBD + OSA: PD patients with both RBD and OSA, *n* = 31. MoCA: Montreal Cognitive Assessment; OSA: Obstructive sleep apnea; RBD: REM sleep behavior disorder; REM: Rapid eye movement; PD: Parkinson\'s disease.](CMJ-131-899-g001){#F1}

Linear regression analysis of the association between Montreal Cognitive Assessment and obstructive sleep apnea or rapid eye movement sleep behavior disorder {#sec2-9}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

We further investigated the association between MoCA scores and OSA or RBD using linear regression analysis \[[Table 4](#T4){ref-type="table"}\]. To reduce the influence of confounding factors such as age, sex, body mass index, education, severity of disease, and other sleep disorders (insomnia and restless legs syndrome), we built multiple models, as a single model, including all the potentially confounding factors, was not feasible because of the correlation between RBD and tonic and phasic EMG activity or between OSA and AHI.

###### 

Linear regression models for the association between MoCA scores and characteristics of OSA or RBD

  MoCA linear regression   *β*      95% confidence internal   *P*
  ------------------------ -------- ------------------------- ---------
  OSA                                                         
   Unadjusted              −0.722   −1.544 to 0.101           0.085
   Model 1                 −0.584   −1.395 to 0.228           0.157
   Model 2                 −0.574   −1.395 to 0.247           0.169
   Model 3                 −0.736   −1.447 to −0.025          0.043
  RBD                                                         
   Unadjusted              −2.480   −3.179 to −1.781          \<0.001
   Model 1                 −2.429   −3.088 to −1.771          \<0.001
   Model 2                 −2.445   −3.106 to −1.784          \<0.001
   Model 3                 −2.575   −3.231 to −1.920          \<0.001
  AHI                                                         
   Unadjusted              −0.054   −0.087 to −0.021          0.002
   Model 1                 −0.046   −0.079 to −0.012          0.008
   Model 2                 −0.046   −0.080 to −0.012          0.008
   Model 3                 −0.052   −0.081 to −0.024          \<0.001
  ODI                                                         
   Unadjusted              −0.061   −0.094 to −0.028          \<0.001
   Model 1                 −0.054   −0.087 to −0.020          0.002
   Model 2                 −0.054   −0.088 to −0.020          0.002
   Model 3                 −0.060   −0.089 to −0.031          \<0.001
  Tonic EMG activity                                          
   Unadjusted              −0.059   −0.100 to −0.019          0.005
   Model 1                 −0.057   −0.104 to −0.011          0.016
   Model 2                 −0.059   −0.105 to −0.012          0.016
   Model 3                 −0.065   −0.119 to −0.012          0.017
  Phasic EMG activity                                         
   Unadjusted              −0.046   −0.087 to −0.004          0.031
   Model 1                 −0.043   −0.088 to 0.001           0.057
   Model 2                 −0.047   −0.093 to −0.002          0.043
   Model 3                 −0.051   −0.102 to −0.001          0.049

Model 1: Adjusted for age, duration, education, and BMI; Model 2: Adjusted for age, duration, education, BMI, UPDRS III score, and Levodopa-equivalent daily dosage; Model 3: Adjusted for age, duration, education, BMI, UPDRS III score, Levodopa-equivalent daily dosage, insomnia, restless legs syndrome, RBD, or OSA. MoCA: Montreal Cognitive Assessment; OSA: Obstructive sleep apnea; RBD: Rapid eye movement sleep behavior disorder; AHI: Apnea-hypopnea index; ODI: Oxygen desaturation index; EMG: Electromyography; BMI: Body mass index; UPDRS: Unified Parkinson's Disease Rating Scale.

Multiple linear regression analysis revealed a significant association between MoCA score and OSA (adjusted for RBD in Model 3; *β* = −0.736, *P* = 0.043) and between MoCA score and RBD (adjusted for OSA in Model 3; *β* = −2.575, *P* \< 0.001). The adjusted *β* value suggested that for PD patients with RBD, the MoCA score decreased by 2.324. Meanwhile, for PD patients with OSA, the MoCA score decreased by 0.743. To further characterize the relationship between MoCA score and severity of OSA and RBD, we performed linear regression analyses to assess the effect of AHI, ODI, and tonic/phasic EMG activity on MoCA score. The differences we found remained significant after adjustment. The adjusted *β* value indicated that MoCA score decreased by 0.57 for every 10 unit increase in AHI.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

In this study, we used PSG to evaluate sleep-related disorders in PD patients. Our results revealed that excessive EMG activity in PD patients with RBD might protect patients against reduced minimum SaO~2~ occurring in PD patients with OSA, and cognitive performance was worse in PD patients with RBD or OSA than in those patients without those conditions.

In terms of the higher minimum SaO~2~ in PD patients with RBD, RBD was protective of OSA severity as evaluated by the minimum SaO~2~. This phenomenon was supported by two of our findings: (1) the minimum SaO~2~ in REM sleep was significantly higher in PD patients with RBD and (2) PD + RBD + OSA patients had higher minimum SaO~2~ in both whole sleep and in REM sleep than PD + OSA patients. Our previous research, which found lower AHI and ODI during REM sleep in PD + RBD patients, verifies this result as well.\[[@ref26]\] This is consistent with another study which found that PD patients with increased muscle tone during sleep had lower OSA severity.\[[@ref7]\] However, another study conducted on 46 PD patients reached the opposite conclusion.\[[@ref12]\] This discrepancy could be explained by the relatively small sample size in their study. The possible mechanism for higher minimum SaO~2~ in PD + RBD patients may be the loss of atonia in upper airway dilator muscles. Another explanation is that drugs that might increase muscle activity could also benefit OSA, such as paroxetine, mirtazapine, and glycinergic antagonists.\[[@ref27][@ref28]\] Some investigators obtained similar results, finding that, in idiopathic RBD patients, OSA severity was also alleviated.\[[@ref10]\]

OSA and RBD may each play a negative role in the cognitive impairment of PD patients. PD + OSA patients were more likely to have memory dysfunction, while PD + RBD and PD + RBD + OSA patients exhibited impairment in the visuospatial/executive, attention, and memory domains. However, differences between the PD + RBD + OSA and PD + RBD/PD + OSA groups were not statistically significant. Prior research also found executive and attention domain impairment in PD + OSA patients.\[[@ref29]\] The use of different tests to evaluate cognitive function could account for this disparity in results. The mechanism for the severe cognitive impairment in PD patients with OSA may include hypoxemia and sleep fragmentation, which may aggravate the dysfunction of the locus coeruleus and multiple other brain areas. On the other hand, for PD patients with RBD, the dysfunction of the pedunculopontine nucleus and cholinergic system plays an important role in their cognitive impairment.\[[@ref30]\]

In our study, linear regression models showed that cognitive impairment severity was associated with OSA and RBD. In our participants, MoCA score for PD patients with RBD declined by 2.575 points and by 0.736 points for PD patients with OSA. As the negative effect of RBD on cognition was larger than that of OSA, the higher minimum SaO~2~ in PD patients with RBD did not counteract the negative effect of RBD on cognitive impairment. Few interventions effectively protect cognition in PD. However, a previous research has explored the association between cognition and RBD or OSA in PD patients.\[[@ref16][@ref31][@ref32]\] Our finding that PD patients with RBD or OSA experienced greater cognitive impairment was consistent with previous reports. We also investigated the interaction between RBD and OSA and quantified their effect on cognition. Our study revealed that higher AHI may exacerbate PD cognitive dysfunction. However, whether treatment with continuous positive airway pressure (CPAP) benefits cognition in PD patients remains to be demonstrated.\[[@ref6][@ref29][@ref33]\] At present, the longest follow-up duration for CPAP treatment is 3 months, and they found no significant changes in neuropsychological scores after CPAP treatment.\[[@ref29]\] The effects of CPAP in PD patients over a longer follow-up period need to be studied.

This study had several limitations. First, the PD + OSA group had a relatively small sample size. Second, we only used MoCA, a multidomain screening tool, to evaluate for cognitive dysfunction. Future studies should employ more detailed neuropsychological tests to assess further domains in which the patient is impaired. Third, we did investigate mild cognitive impairment, which can be a manifestation of numerous complex pathological processes.\[[@ref34]\] We plan to evaluate the effect of CPAP on cognitive deficits in PD patients with OSA in futures studies because previous research indicates that cognition partially improves in OSA patients after CPAP treatment.\[[@ref35]\]

In conclusion, we found that RBD alleviated OSA severity; however, RBD and OSA together exacerbated PD cognitive impairment. Further studies are needed to evaluate whether OSA treatment can improve cognition in PD.
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